<table id="table8" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 8. Effect of Voriconazole on Pharmacokinetics of Other Drugs [see <linkhtml href="#s12.3">Clinical Pharmacology (12.3)</linkhtml>]</caption>
<col align="left" valign="top" width="33%"></col>
<col align="center" valign="top" width="33%"></col>
<col align="center" valign="top" width="34%"></col>
<thead>
<tr>
<th align="center" stylecode="Lrule">Drug/Drug Class<br/>(Mechanism of  Interaction by Voriconazole)</th>
<th stylecode="Lrule">Drug Plasma Exposure<br/>(C<sub>max</sub> and AUC<sub>τ</sub>)</th>
<th stylecode="Lrule Rrule">Recommendations for Drug  Dosage Adjustment/Comments</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Sirolimus<footnote id="t8f1">Results based on <content stylecode="italics">in vivo</content> clinical studies generally following repeat oral dosing with 200 mg BID voriconazole to healthy subjects</footnote>
<br/>(CYP3A4 Inhibition)</td>
<td stylecode="Rrule">Significantly Increased</td>
<td stylecode="Rrule">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Rifabutin<footnoteref idref="t8f1"></footnoteref>
<br/>(CYP3A4 Inhibition)</td>
<td stylecode="Rrule">Significantly Increased</td>
<td stylecode="Rrule">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Efavirenz<footnote id="t8f2">Results based on <content stylecode="italics">in </content>
<content stylecode="italics">vivo</content> clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for at least 2 days voriconazole to healthy subjects</footnote>
<br/>(CYP3A4 Inhibition)</td>
<td stylecode="Rrule">Significantly Increased</td>
<td stylecode="Rrule">When voriconazole is coadministered with efavirenz, voriconazole oral maintenance dose should be increased to 400 mg q12h and efavirenz should be decreased to 300 mg q24h</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">High-dose Ritonavir (400 mg q12h)<footnoteref idref="t8f2"></footnoteref>(CYP3A4 Inhibition)</td>
<td stylecode="Rrule">No Significant Effect of Voriconazole on Ritonavir C<sub>max</sub> or AUC<sub>τ</sub>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Contraindicated</content> because of significant reduction of voriconazole C<sub>max</sub> and AUC<sub>τ</sub>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule"> </td>
<td stylecode="Rrule"> </td>
<td stylecode="Rrule"> </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Low-dose Ritonavir (100 mg q12h)<footnoteref idref="t8f2"></footnoteref>
</td>
<td stylecode="Rrule">Slight Decrease in Ritonavir C<sub>max</sub> and AUC<sub>τ</sub>
</td>
<td stylecode="Rrule">Coadministration of voriconazole and low-dose ritonavir (100 mg q12h) should be avoided (due to the reduction in voriconazole C<sub>max</sub> and AUC<sub>τ</sub>) unless an assessment of the benefit/risk to the patient justifies the use of voriconazole</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Terfenadine, Astemizole, Cisapride, Pimozide, Quinidine<br/>(CYP3A4 Inhibition)</td>
<td stylecode="Rrule">Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased</td>
<td stylecode="Rrule">
<content stylecode="bold">Contraindicated </content>because of potential for QT prolongation and rare occurrence of <content stylecode="italics">torsade de pointes</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ergot Alkaloids<br/>(CYP450 Inhibition)</td>
<td stylecode="Rrule">Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased</td>
<td stylecode="Rrule">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Cyclosporine<footnoteref idref="t8f1"></footnoteref>
<br/>(CYP3A4 Inhibition)</td>
<td stylecode="Rrule">AUC<sub>τ</sub> Significantly Increased; No Significant Effect on C<sub>max</sub>
</td>
<td stylecode="Rrule">When initiating therapy with VFEND in patients already receiving cyclosporine, reduce the cyclosporine dose to one-half of the starting dose and follow with frequent monitoring of cyclosporine blood levels. Increased cyclosporine levels have been associated with nephrotoxicity. When VFEND is discontinued, cyclosporine concentrations must be frequently monitored and the dose increased as necessary.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Methadone<footnote>Results based on <content stylecode="italics">in </content>
<content stylecode="italics">vivo</content> clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for 4 days voriconazole to subjects receiving a methadone maintenance dose (30–100 mg QD)</footnote> (CYP3A4 Inhibition)</td>
<td stylecode="Rrule">Increased</td>
<td stylecode="Rrule">Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation. Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration. Dose reduction of methadone may be needed</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Fentanyl (CYP3A4 Inhibition)<br/>
</td>
<td stylecode="Rrule">Increased</td>
<td align="left" stylecode="Rrule">Reduction in the dose of fentanyl and other long-acting opiates metabolized by CYP3A4 should be considered when coadministered with VFEND. Extended and frequent monitoring for opiate-associated adverse events may be necessary [<content stylecode="italics">see <linkhtml href="#s7">Drug Interactions (7)</linkhtml>
</content>]</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Alfentanil (CYP3A4 Inhibition)</td>
<td stylecode="Rrule">Significantly Increased</td>
<td stylecode="Rrule">Reduction in the dose of alfentanil and other opiates metabolized by CYP3A4 (e.g., sufentanil) should be considered when coadministered with VFEND. A longer period for monitoring respiratory and other opiate-associated adverse events may be necessary [<content stylecode="italics">see <linkhtml href="#s7">Drug Interactions (7)</linkhtml>
</content>].</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Oxycodone (CYP3A4 Inhibition)</td>
<td stylecode="Rrule">Significantly Increased</td>
<td align="left" stylecode="Rrule">Reduction in the dose of oxycodone and other long-acting opiates metabolized by CYP3A4 should be considered when coadministered with VFEND. Extended and frequent monitoring for opiate-associated adverse events may be necessary [<content stylecode="italics">see <linkhtml href="#s7">Drug Interactions (7)</linkhtml>
</content>].</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">NSAIDs<footnote>Non-Steroidal Anti-Inflammatory Drug</footnote> including. ibuprofen and diclofenac<br/>(CYP2C9 Inhibition)</td>
<td stylecode="Rrule">Increased</td>
<td align="left" stylecode="Rrule">Frequent monitoring for adverse events<br/>and toxicity related to NSAIDs. Dose reduction of NSAIDs may be needed [<content stylecode="italics">see <linkhtml href="#s7">Drug Interactions (7)</linkhtml>
</content>].</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Tacrolimus<footnoteref idref="t8f1"></footnoteref>
<br/>(CYP3A4 Inhibition)</td>
<td stylecode="Rrule">Significantly Increased</td>
<td stylecode="Rrule">When initiating therapy with VFEND in patients already receiving tacrolimus, reduce the tacrolimus dose to one-third of the starting dose and follow with frequent monitoring of tacrolimus blood levels. Increased tacrolimus levels have been associated with nephrotoxicity. When VFEND is discontinued, tacrolimus concentrations must be frequently monitored and the dose increased as necessary.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Phenytoin<footnoteref idref="t8f1"></footnoteref>
<br/>(CYP2C9 Inhibition)</td>
<td stylecode="Rrule">Significantly Increased</td>
<td stylecode="Rrule">Frequent monitoring of phenytoin plasma concentrations and frequent monitoring of adverse effects related to phenytoin.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Oral Contraceptives containing ethinyl estradiol and norethindrone (CYP3A4 Inhibition)<footnoteref idref="t8f2"></footnoteref>
</td>
<td stylecode="Rrule">Increased</td>
<td stylecode="Rrule">Monitoring for adverse events related to oral contraceptives is recommended during coadministration.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Warfarin<footnoteref idref="t8f1"></footnoteref>
<br/>(CYP2C9 Inhibition)</td>
<td stylecode="Rrule">Prothrombin Time Significantly Increased</td>
<td stylecode="Rrule">Monitor PT or other suitable anti-coagulation tests. Adjustment of warfarin dosage may be needed.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Omeprazole<footnoteref idref="t8f1"></footnoteref>
<br/>(CYP2C19/3A4 Inhibition)</td>
<td stylecode="Rrule">Significantly Increased</td>
<td stylecode="Rrule">When initiating therapy with VFEND in patients already receiving omeprazole doses of 40 mg or greater, reduce the omeprazole dose by one-half. The metabolism of other proton pump inhibitors that are CYP2C19 substrates may also be inhibited by voriconazole and may result in increased plasma concentrations of other proton pump inhibitors.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Other HIV Protease Inhibitors<br/>(CYP3A4 Inhibition)</td>
<td stylecode="Rrule">
<content stylecode="italics">In Vivo</content> Studies Showed No Significant Effects on Indinavir Exposure</td>
<td stylecode="Rrule">No dosage adjustment for indinavir when coadministered with VFEND</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism<br/>(Increased Plasma Exposure)</td>
<td stylecode="Rrule">Frequent monitoring for adverse events and toxicity related to other HIV protease inhibitors</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Other NNRTIs<footnote>Non-Nucleoside Reverse Transcriptase Inhibitors</footnote>
<br/>(CYP3A4 Inhibition)</td>
<td stylecode="Rrule">A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the  Potential for Voriconazole to Inhibit Metabolism of Other NNRTIs<br/>(Increased Plasma Exposure)</td>
<td stylecode="Rrule">Frequent monitoring for adverse events and toxicity related to NNRTI</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Benzodiazepines<br/>(CYP3A4 Inhibition)</td>
<td stylecode="Rrule">
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism<br/>(Increased Plasma Exposure)</td>
<td stylecode="Rrule">Frequent monitoring for adverse events and toxicity (i.e., prolonged sedation) related to benzodiazepines metabolized by CYP3A4 (e.g., midazolam, triazolam, alprazolam). Adjustment of benzodiazepine dosage may be needed.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">HMG-CoA Reductase Inhibitors (Statins)<br/>(CYP3A4 Inhibition)</td>
<td stylecode="Rrule">
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism<br/>(Increased Plasma Exposure)</td>
<td stylecode="Rrule">Frequent monitoring for adverse events and toxicity related to statins. Increased statin concentrations in plasma have been associated with rhabdomyolysis. Adjustment of the statin dosage may be needed.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Dihydropyridine Calcium Channel Blockers<br/>(CYP3A4 Inhibition)</td>
<td stylecode="Rrule">
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism<br/>(Increased Plasma Exposure)</td>
<td stylecode="Rrule">Frequent monitoring for adverse events and toxicity related to calcium channel blockers. Adjustment of calcium channel blocker dosage may be needed.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Sulfonylurea Oral Hypoglycemics<br/>(CYP2C9 Inhibition)</td>
<td stylecode="Rrule">Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased</td>
<td stylecode="Rrule">Frequent monitoring of blood glucose and for signs and symptoms of hypoglycemia. Adjustment of oral hypoglycemic drug dosage may be needed.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Vinca Alkaloids<br/>(CYP3A4 Inhibition)</td>
<td stylecode="Rrule">Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased</td>
<td stylecode="Rrule">Frequent monitoring for adverse events and toxicity (i.e., neurotoxicity) related to vinca alkaloids. Adjustment of vinca alkaloid dosage may be needed.</td>
</tr>
</tbody>
</table>